Bone surgery robotics
Series C from
Exclusive advisor to the company
Enovis (NYSE: ENOV) made a binding offer to acquire eCential Robotics at an upfront enterprise value of €155 million, with up to €35 million in milestone payments tied to the knee and shoulder programmes. eCential's spine surgery robot brings Enovis the robotics capability its offering lacked. Existing shareholders, including Bpifrance, Sigma Gestion and Med-Innov, are selling their shares. Closing is expected in the fourth quarter of 2026.
Read the case study
Bone surgery robotics
Series C from
Bone surgery robotics
€10.5M Series A from
Bone surgery robotics
Seed round from
Sale, acquisition or capital raising: write to us and we will get back to you shortly.